Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer

Podcast

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
Stephanie L. Graff, MD
Malinda West, MD
Marina Sharifi, MD, PhD
Related Content

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Trastuzumab Biosimilar Receives CHMP Recommendation for HER2+ Breast and Gastric Cancer

September 18th 2023

Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer

September 14th 2023

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

NDA Submission Planned for EA-114 in Metastatic Breast Cancer Following Positive Type C Meeting With FDA

August 30th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Trastuzumab Biosimilar Receives CHMP Recommendation for HER2+ Breast and Gastric Cancer

September 18th 2023

Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer

September 14th 2023

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

NDA Submission Planned for EA-114 in Metastatic Breast Cancer Following Positive Type C Meeting With FDA

August 30th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Trastuzumab Biosimilar Receives CHMP Recommendation for HER2+ Breast and Gastric Cancer

September 18th 2023

Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer

September 14th 2023

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

NDA Submission Planned for EA-114 in Metastatic Breast Cancer Following Positive Type C Meeting With FDA

August 30th 2023